A Pilot Trial of Enoxaparin versus Aspirin in Patients with Cancer and Stroke

Protocol
12-264
Full Title
A Pilot Trial of Enoxaparin Versus Aspirin in Patients with Cancer and Stroke
Phase
Pilot
Purpose

Patients with cancer who have a stroke are at high risk for a future stroke or other blood clotting problems. These patients are routinely treated with blood thinners such as aspirin or enoxaparin. However, it is unclear which medicine is best.

In this study, investigators are comparing aspirin versus enoxaparin in people with cancer who recently had a stroke, and to see if it is possible to do clinical trials comparing blood thinners in this patient population. Patients will receive either a subcutaneous (under the skin) injection of enoxaparin twice a day, or aspirin (by mouth) every day for six months, and researchers will compare the two groups.

Eligibility

This study will include patients with active systemic cancer (ages 18 to 85) who were diagnosed at Memorial Sloan-Kettering Cancer Center with acute ischemic stroke within two weeks of entering the study.

For more information about this study, please contact Dr. Lisa DeAngelis at 212-639-7123.

Disease(s)
Solid Tumors